Articles tagged "Heart"

2019 American Transplant Congress
Tolerance to ABO A-Antigen Following Treatment of Infant Mice with A-Expressing MHC-Identical Erythrocytes
B. Motyka¹, J. Fersovich¹, M. Sulzer¹, I. Adam¹, J. Pearcey¹, K. Tao¹, C. W. Cairo², P. J. Cowan³, L. J. West¹
¹Dept Pediatrics, Alberta Transplant Institute, Canadian Donation and Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ²Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ³Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia
*Purpose: ABO-incompatible heart transplantation (ABOi HTx) is safe in young children and increases donor access. Post-ABOi HTx, B cell tolerance develops to donor ABO blood…
2019 American Transplant Congress
Unfair Waiting Time Calculation? Impact of Accumulated Wait Time Restart with a Decrease in Status from 1A to 1B or 2 on Mortality of Heart Transplant Candidates
S. Yu, M. Kosztowski, M. Waldram, D. L. Segev, A. B. Massie
Department of Surgery, Johns Hopkins, Baltimore, MD
*Purpose: Between two heart transplant (HT) candidates listed at the same status, the candidate with longer accumulated wait time receives higher waitlist priority; under current…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
A Molecular Analysis of Graft Survival in the INTERHEART Study
P. Halloran¹, J. Reeve and the INTERHEART investigators²
¹University of Alberta, Edmonton AB, AB, Canada, ²ATAGC, University of Alberta, Edmonton AB, AB, Canada
*Purpose: Rejection is a major cause of graft loss in heart and kidney transplants. The principal diagnosis associated with risk in kidneys is antibody-mediated rejection…
2019 American Transplant Congress
Anemia and Hemolysis on Dapsone Despite Normal Glucose-6-Phosphate Dehydrogenase Activity in Heart Transplant Recipients
K. Lor, E. Kransdorf, J. Patel, M. Kittleson, D. Chang, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Dapsone has been considered an acceptable alternative for pneumocystis jirovecii pneumonia (PCP) prophylaxis in sulfa-allergic or -intolerant transplant patients with normal glucose-6-phosphate dehydrogenase (G6PD)…
2019 American Transplant Congress
TMA Development in Kidney and Heart Xenografts Treated with Anti-CD40 or Anti-CD154 Antibodies
D. H. Ma¹, H. Sasaki¹, J. M. O¹, K. Ahrens¹, D. Becerra¹, C. G. Rickert¹, D. M. Detelich¹, T. Oura¹, W. Somer¹, I. Rosales², R. N. Pierson¹, J. Markmann¹, J. C. Madsen¹, T. Kawai¹
¹Surgery, MGH, Boston, MA, ²Pathology, MGH, Boston, MA
*Purpose: Genetically modified Galactose-α 1,3-galactose knockout transgenic swine expressing human CD55 (GTKO.hCD55) are resistant to hyperacute rejection of xenografts. We compare anti-CD154 and anti-CD40 antibody-based…
2019 American Transplant Congress
Low Frequency Of Canonical Human Leukocyte Antigen Alloimmunization In Heart Transplantation Candidates With Ventricular Assist Devices
G. K. Mahowald¹, S. L. Saidman¹, G. Lewis², V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Cardiology, Massachusetts General Hospital, Boston, MA
*Purpose: Screening for anti-HLA antibodies in heart transplantation candidates is complicated by transfusions as well as by the presence of ventricular assist devices (VADs), which…
2019 American Transplant Congress
Outcome Of Left Main Stenting After Heart Transplantation
S. Dimbil, J. Patel, B. Azarbal, M. Kittleson, R. Levine, D. H. Chang, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Cardiac allograft vasculopathy (CAV) is one of the major factors limiting long-term survival after HTx. The use of angioplasty and drug-eluting stents is common…
2019 American Transplant Congress
Perioperative Cardiac Xenograft Dysfunction after Orthotopic Transplantation is for Real
M. Mohiuddin¹, A. Singh¹, L. DiChiacchio¹, D. Kaczorowski¹, B. Lewis¹, T. Zhang¹, F. Sentz¹, I. Tatarov¹, D. Parsell¹, P. Odonkor¹, E. Strauss¹, B. Williams¹, K. Deatrick¹, D. Ayares², B. Griffith¹, S. Bartlett¹
¹Department of Surgery, University of Maryland Baltimore, Baltimore, MD, ²Revivicor, Inc, Blacksburg, VA
*Purpose: After successful prolongation of cardiac xenograft survival in a heterotopic position, the next step is to evaluate genetically engineered (GE) pig hearts for their…
2019 American Transplant Congress
Myeloid AXL Promotes Cardiac Allograft Vasculopathy
K. E. Glinton¹, X. Yeap¹, Z. J. Zhang², X. Luo³, E. B. Thorp¹
¹Pathology, FCVRRI, Northwestern University - Feinberg School of Medicine, Chicago, IL, ²Surgery, Northwestern University - Feinberg School of Medicine, Chicago, IL, ³Duke Transplant Center, Duke University School of Medicine, Durham, NC
*Purpose: Cardiac Allograft Vasculopathy (CAV) is a significant contributor to long term transplant rejection, despite advances in immunotherapy. Reactivity to alloantigen presentation may occur by…